← Back to Search

PD-1 Inhibitor

PF-07209960 for Colorectal Cancer

Phase 1

Waitlist Available

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through up to 2 years

Awards & highlights

Study Summary

This trial is testing a new drug, PF-07209960, to see if it is safe and effective in treating people with locally advanced or metastatic solid tumors. The trial has two parts: first, researchers will test different doses of the drug to see what is safe and effective (dose escalation); then, they will test the drug at the recommended dose in people with specific types of tumors (dose expansion).

Eligible Conditions

Colorectal Cancer
Ovarian Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Kidney Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with adverse events (AEs)

Number of participants with clinically significant laboratory abnormalities

Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1)

+1 more

Secondary outcome measures

Disease control rate (DCR)

Duration of response (DOR)

Immunogenicity in Expansion Cohorts (Part 2)

+12 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Dose Expansion (Part 2) - Cohort 3 (UC)Experimental Treatment1 Intervention

Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1

Group II: Dose Expansion (Part 2) - Cohort 2 (RCC)Experimental Treatment1 Intervention

Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1

Group III: Dose Expansion (Part 2) - Cohort 1 (NSCLC)Experimental Treatment1 Intervention

Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1

Group IV: Dose Escalation (Part 1)Experimental Treatment1 Intervention

Participants will receive PF-07209960 at escalating dose levels

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor

4,570 Previous Clinical Trials

10,915,989 Total Patients Enrolled

Pfizer CT.gov Call CenterStudy DirectorPfizer

3,476 Previous Clinical Trials

8,092,184 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How widely available is this test being conducted in our state?

"15 medical sites across the United States are facilitating this clinical trial. Examples include City of Hope Investigational Drug Service (IDS) in Duarte, Seattle Cancer Care Alliance in Seattle, and UCLA Hematology Oncology - Santa Monica in Santa Monica. Additionally, there are a further dozen research centres taking part."

Answered by AI

What goals is this research endeavor attempting to achieve?

"This clinical trial will evaluate the Number of participants with clinically significant laboratory abnormalities over a Baseline through 28 days after first dose (Cycle 1) period as its primary outcome. The Secondary outcomes include Single Dose Area Under the Curve within one dosing interval (AUCtau), Intratumor T cells in pre-treatment vs. on-treatment tumor biopsy samples for Expansion Cohorts (Part 2), and Multiple Dose Area Under the curve within one dose interval at steady state (AUCtau,ss)."

Answered by AI

Has the regulatory body allowed for the commercialization of PF-07209960?

"Due to the fact that PF-07209960 is only in its first phase of clinical trials, our team at Power has estimated a safety score of 1 for this medication. This reflects the limited evidence available regarding safety and efficacy."

Answered by AI

Is the call for volunteers to partake in this research still open?

"As per the records on clinicaltrials.gov, this trial is not presently enrolling individuals. This study was first introduced to the public on December 16th 2020 and last updated October 10th 2022; however, 3689 other trials are actively seeking participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

2020. "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04628780.